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Significant morbidity is associated with the synergistic
and inhibitory interactions of bacteria, viruses, parasites,
and fungi. The oral cavity, gut, and genitourinary tract
are home to many of these organisms and are the site of
virus-associated malignancies that affect millions world-
wide. Yet little is known with regard to the cellular and
molecular interactions of viral pathogens with the nor-
mal flora as well as the interactions among pathogens
themselves. Our laboratory is interested in understand-
ing the role of factors present within the immediate
environment that may influence reactivation of persis-
tent infection and pathogenesis. Our central hypothesis
is that viral-bacterial interactions foster enhanced patho-
gen replication and modulation of the immune response
in the mouth, GI tract, and genito-urinary tract. The
detection of replicating virus in these tissues has incited
investigation into the relationship between bacterial
infection and herpesviral reactivation. We hypothesized
that bacterial end-products including short chain fatty
acids (SCFA), lipopolysaccharide (LPS), and lipoteichoic
acid (LTA) secreted by oral bacteria initiate viral reacti-
vation from latency. Latently infected EBV, KSHV, and
MHV 68 cell lines were incubated with crude spent
media containing secreted SCFA, and components of
bacterial pathogens (E. faecalis, Bacteriodes, Prevotella,
Porphomonas, and Fusiobacterium Nucleatum). Cells
were then assayed for viral promoter activation, promo-
ter-protein interactions, and state of infection. Following
incubation with crude spent media, viral immediate
early promoters were activated, the viral early genes
were upregulated as determined by RT PCR and western
blot, and linear genomes were detected. HDAC inhibi-
tion activity as well as protein kinase C activity
increased significantly following treatment with bacterial
spent media. KSHV and EBV were consistently reacti-
vated by bacterial metabolites but the mechanism of
reactivation was both bacteria, virus, and cell type speci-
fic. Interestingly, EBV was preferentially reactivated fol-
lowing toll like receptor stimulation while KSHV and
HSV-1 reactivation occurred following HDAC inhibi-
tion. In conclusion, these studies provide significant
insights to gammaherpesreactivation that may occur in
vivo via pathogen-pathogen interaction.
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